The health regulator’s decision allows use of the therapy, branded as Elrexfio, in patients with multiple myeloma that is hard to treat or has come back after receiving four or more prior lines of certain classes of treatments.
Posts
Pfizer forecasted stable growth in the coming years, driven by a strong product push to cushion its non-COVID business and exclusivity losses, according to company chairman and Chief Executive Officer Albert Bourla, M.D., Monday.
